Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
1.430
-0.010 (-0.69%)
At close: Dec 5, 2025, 4:00 PM EST
1.490
+0.060 (4.20%)
After-hours: Dec 5, 2025, 7:22 PM EST
Sunshine Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 37.32 | 34.87 | 24.09 | 4.35 | 0.23 | 0.07 | Upgrade
|
| Revenue Growth (YoY) | 13.24% | 44.75% | 454.42% | 1802.41% | 219.88% | 238.10% | Upgrade
|
| Cost of Revenue | 25 | 24.2 | 15.75 | 2.65 | 0.12 | 0.03 | Upgrade
|
| Gross Profit | 12.32 | 10.67 | 8.34 | 1.7 | 0.11 | 0.05 | Upgrade
|
| Selling, General & Admin | 15.75 | 14.94 | 10.83 | 9.48 | 1.87 | 0.61 | Upgrade
|
| Research & Development | 0.68 | 0.93 | 1.86 | 0.81 | 0.67 | 0 | Upgrade
|
| Other Operating Expenses | 0.45 | 0.39 | 0.29 | 0.06 | - | - | Upgrade
|
| Operating Expenses | 17.18 | 16.48 | 13.12 | 10.37 | 2.55 | 0.62 | Upgrade
|
| Operating Income | -4.86 | -5.81 | -4.79 | -8.67 | -2.44 | -0.58 | Upgrade
|
| Interest Expense | -0.01 | -0.01 | -0.14 | -0.04 | -0.33 | -0.17 | Upgrade
|
| Interest & Investment Income | 0.32 | 0.5 | 0.81 | 0.52 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.34 | -0.04 | -0 | -0 | 0 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | -4.88 | -5.37 | -4.11 | -8.2 | -2.77 | -0.74 | Upgrade
|
| Impairment of Goodwill | - | - | - | -18.33 | - | - | Upgrade
|
| Asset Writedown | -1.62 | - | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.01 | -9.67 | -2.05 | Upgrade
|
| Pretax Income | -6.51 | -5.37 | -4.11 | -26.51 | -12.44 | -2.78 | Upgrade
|
| Income Tax Expense | -0.52 | -0.23 | 0.4 | 0.23 | - | - | Upgrade
|
| Earnings From Continuing Operations | -5.99 | -5.13 | -4.51 | -26.74 | -12.44 | -2.78 | Upgrade
|
| Net Income | -5.99 | -5.13 | -4.51 | -26.74 | -12.44 | -2.78 | Upgrade
|
| Net Income to Common | -5.99 | -5.13 | -4.51 | -26.74 | -12.44 | -2.78 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 1 | 0 | - | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 1 | 0 | - | - | - | Upgrade
|
| Shares Change (YoY) | 1977.26% | 5371.73% | - | - | - | - | Upgrade
|
| EPS (Basic) | -1.72 | -7.32 | -351.35 | - | - | - | Upgrade
|
| EPS (Diluted) | -1.72 | -7.32 | -351.35 | - | - | - | Upgrade
|
| Free Cash Flow | -7.4 | -14.19 | -8.86 | -5.44 | -1.83 | -0.66 | Upgrade
|
| Free Cash Flow Per Share | -2.13 | -20.22 | -690.63 | - | - | - | Upgrade
|
| Gross Margin | 33.01% | 30.59% | 34.61% | 39.04% | 48.42% | 63.80% | Upgrade
|
| Operating Margin | -13.02% | -16.67% | -19.86% | -199.61% | -1068.24% | -807.83% | Upgrade
|
| Profit Margin | -16.06% | -14.72% | -18.70% | -615.44% | -5444.41% | -3898.74% | Upgrade
|
| Free Cash Flow Margin | -19.84% | -40.68% | -36.76% | -125.24% | -800.75% | -922.13% | Upgrade
|
| EBITDA | -4.56 | -5.59 | -4.64 | -8.65 | -2.43 | -0.56 | Upgrade
|
| EBITDA Margin | -12.22% | -16.02% | -19.24% | -199.03% | - | - | Upgrade
|
| D&A For EBITDA | 0.3 | 0.22 | 0.15 | 0.03 | 0.01 | 0.01 | Upgrade
|
| EBIT | -4.86 | -5.81 | -4.79 | -8.67 | -2.44 | -0.58 | Upgrade
|
| EBIT Margin | -13.02% | -16.67% | -19.86% | -199.61% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.